20th Oct 2020 14:18
Angle PLC - liquid biopsy company based in Guildford - Says the US Food & Drug Administration has accepted its full Class II De Novo FDA Submission seeking clearance of its Parsortix cell separation system for use with metastatic breast cancer patients. Notes it believes the earliest prospect of clearance by the regulatory body is the first quarter of 2021.
"We are pleased that our FDA submission has successfully completed FDA administrative review and is now in substantive review. We believe there is a tremendous opportunity for Angle to secure the first ever FDA clearance for a platform that captures and harvests intact circulating tumour cells from patient blood for subsequent analysis, in the first instance for metastatic breast cancer," says Founder & Chief Executive Andrew Newland.
Current stock price: 49.99 pence
Year-to-date change: down 20%
By Ife Taiwo; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Angle